Back to search results
NCT05997914

Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation

Enrolling by Invitation
NAAges 18+InterventionalPrevention
University of Massachusetts, Worcester
~80 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Storytelling Intervention

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Fidelity via viewing time
Measured over 90 days from randomization
+6 more outcomes measured

Conditions

Atrial Fibrillation
Atrial Flutter
Adherence, Medication
Anticoagulants and Bleeding Disorders
Stroke
Bleeding
Narration

Explore related trials

Atrial FibrillationAtrial Flutter

Where it's being run

4 sites across 3 states
Massachusetts2
Florida1
Michigan1

Study leadership

  • Alok Kapoor, MD · PRINCIPAL_INVESTIGATOR · UMass Chan Medical School

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

African-American patients aged 18 or older with elevated stroke risk (CHA2DS2-VASc ≥2 for men and ≥3 for women) who are not currently on anticoagulation (AC) but for whom a cardiology provider or primary care provider at the two study sites recommended AC recently

Exclusion

Non-African American and other non-Black patients under the age of 18 patients without an ICD-10 diagnostic code consistent with AF or atrial fibrillation or atrial flutter
Patient without a visit with a primary care provider, cardiovascular medicine specialist, or ambulatory care provider in the previous one year
Patient who is pregnant or a prisoner.
Patients with left atrial appendage surgery or device, hospice status, ongoing bleeding, and intracranial bleeding in intralobar territory

What this trial measures

  • Fidelity via viewing time90 days from randomization

    Time spent viewing videos

  • Fidelity via transportation90 days from randomization

    In intervention patients, measure transportation (absorption into a story) using a transportation scale short form where the minimum and maximum values are 1 (Not at all) and 7 (Very much), respectively. Higher scores mean a better outcome (high transportation).

  • Feasibility in terms of recruitment rates90 days from randomization

    The investigators will calculate the proportion of patients recruited as well as the recruitment rate. The recruitment proportion will be the number of patients randomized over the total of patients approached. The recruitment rate will be the total time (in days) required to recruit the randomized sample.

  • Feasibility in terms of retention rates90 days from randomization

    The investigators will calculate the per-group retention proportion as the number of individuals from each group remaining in the study after its completion over the total randomized to that group.

  • Acceptability of participating in the study90 days from randomization

    Participants will be asked to use an acceptability scale (which the investigators will develop later during the study) to rate their agreement with statements about the acceptability of using the video website, completing the transportation scale short survey (intervention participants only), and participating in the study in general.

  • Video testing on anticoagulation initiation behavior6 months from randomization

    The investigators will review charts (electronic medical records) of study participants for frequency of anticoagulation (AC) initiation (switch from being off AC to being on AC) in intervention vs. controls over the six months from randomization in patients who start AC.

  • Video testing on anticoagulation persistence behavior6 months from randomization

    The investigators will review charts (electronic medical records) of study participants for anticoagulation (AC) persistence (duration of AC use measured in days from baseline) in intervention vs. controls over the six months from randomization in patients who start AC.